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Abstract
The uniqueness of UCP1 (as compared to UCP2/UCP3) is evident from expression analysis and ablation studies. UCP1
expression is positively correlated with metabolic inefficiency, being increased by cold acclimation (in adults or perinatally)
and overfeeding, and reduced in fasting and genetic obesity. Such a simple relationship is not observable for UCP2/UCP3.
Studies with UCP1-ablated animals substantiate the unique role of UCP1: the phenomenon of adaptive adrenergic non-
shivering thermogenesis in the intact animal is fully dependent on the presence of UCP1, and so is any kind of cold
acclimation-recruited non-shivering thermogenesis; thus UCP2/UCP3 (or any other proteins or metabolic processes) cannot
substitute for UCP1 physiologically, irrespective of their demonstrated ability to show uncoupling in reconstituted systems or
when ectopically expressed. Norepinephrine-induced thermogenesis in brown-fat cells is absolutely dependent on UCP1, as is
the uncoupled state and the recoupling by purine nucleotides in isolated brown-fat mitochondria. Although very high UCP2/
UCP3 mRNA levels are observed in brown adipose tissue of UCP1-ablated mice, there is no indication that the isolated
brown-fat mitochondria are uncoupled; thus, high expression of UCP2/UCP3 does not necessarily confer to the
mitochondria of a tissue a propensity for being innately uncoupled. Whereas the thermogenic effect of fatty acids in brown-
fat cells is fully UCP1-dependent, this is not the case in brown-fat mitochondria; this adds complexity to the issues
concerning the mechanisms of UCP1 function and the pathway from L3-adrenoceptor stimulation to UCP1 activation and
thermogenesis. In addition to amino acid sequences conserved in all UCPs as part of the tripartite structure, all UCPs contain
certain residues associated with nucleotide binding. However, conserved amongst all UCP1s so far sequenced, and without
parallel in all UCP2/UCP3, are two sequences: 144SHLHGIKP and the C-terminal sequence RQTVDC(A/T)T; these
sequences may therefore be essential for the unique thermogenic function of UCP1. The level of UCP1 in the organism is
basically regulated at the transcriptional level (physiologically probably mainly through the L3-adrenoceptor/CREB
pathway), with influences from UCP1 mRNA stability and from the delay caused by translation. It is concluded that UCP1
is unique amongst the uncoupling proteins and is the only protein able to mediate adaptive non-shivering thermogenesis and
the ensuing metabolic inefficiency. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Preamble
In a black box perspective, mammalian metabolic
e⁄ciency may be said to be very close to zero. Thus,
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in general, what goes in, goes out: at the end of the
day, all energy supplied is essentially transformed
into heat ^ with a very small percentage being used
to perform work on the surroundings, or for growth,
or for storage in or extraction from the bodily energy
reserves.
However, on closer examination, it transpires that
there are mechanisms within the body, the sole pur-
pose of which seems to be to transform energy into
heat (Fig. 1). With the main energy equivalent for
cellular work being ATP, any mechanism that trans-
fers substrate energy to heat without ATP synthesis
may be said to have as its outcome a lowering of
metabolic e⁄ciency. Of such mechanisms for ‘uncou-
pling’ in its original sense ^ i.e. uncoupling the pro-
cesses of substrate oxidation from ATP synthesis ^
the one found in brown adipose tissue and catalysed
by the original uncoupling protein UCP1 (thermoge-
nin) [1,2] is the paradigmatic one. To what degree it
is also the only one is presently under discussion.
The theme of the present review is to present evi-
dence that UCP1 is the only protein able to mediate
an adrenergically stimulated adaptive thermogenic
(‘uncoupling’) process with resulting metabolic ine⁄-
ciency, and that UCP1 in this respect distinguishes
itself qualitatively from all other proteins in the
body, including its closest sequence homologues:
UCP2 and UCP3. Based on this physiological back-
ground, we then examine current issues concerning
the physiological control of UCP1 activity and
amount, continuously providing a corollary with
the novel UCPs.
2. Only UCP1 is consistently positively correlated
with physiologically induced decreased metabolic
e⁄ciency
The physiological states that are associated with a
decreased metabolic e⁄ciency include exposure to
cold surroundings, exposure to certain diets and
being newborn. We ¢rst review evidence that UCP1
levels, in each of these cases, are positively correlated
with a decreased metabolic e⁄ciency, whereas such a
correlation is not found consistently concerning
UCP2 and UCP3. As UCP1 is only expressed in
brown adipose tissue, and UCP3 only in brown adi-
pose tissue and muscle, a rather comprehensive sum-
mary of the changes in expression of these UCPs can
be made. Concerning the much more widely distrib-
uted (although not ubiquitous) UCP2, only examples
of tissue expression patterns can be given.
2.1. Cold acclimation
In mammals acutely exposed to cold, the metabol-
ic rate is immediately increased through shivering.
This occurs through physical (although purposeless)
muscular work and involves the synthesis and break-
down of ATP in the muscles, and it therefore does
not represent a true state of metabolic ine⁄ciency as
de¢ned above. However, with time in cold, shivering
ceases [3,4], and the continued high metabolism oc-
curs now through the process of non-shivering ther-
mogenesis. Simultaneously, a recruitment of brown
Fig. 1. What is metabolic ine⁄ciency? In a mitochondrial con-
text, a decreased e⁄ciency may be localised in the respiratory
chain itself, with less than full energy transfer into the proton
electrochemical gradient (1). Even if the energy then is utilised
for ATP synthesis, ATPases may exist that cleave the ATP
without performing ‘work’ (2), and even if ‘work’ is performed
(3), this may be purposeless, as is muscle contraction during
shivering. However, not all protons that are not used for ATP
synthesis are necessarily ‘ine⁄cient’, because most mitochon-
drial anti- and symporters are driven by proton re-entry (4).
Protons may also re-enter the mitochondria in an unregulated
way which is normally interpreted as being ‘wasteful’ (5). In
contrast, what we here de¢ne as ‘ine⁄ciency’ are mechanisms
that allow for a functional re-entry of protons into the mito-
chondria, and that these mechanisms are ‘purposeful’ for the
organism and in some way regulated. It is the contention of the
present review that it is only the paradigmatic uncoupling pro-
tein-1 (UCP1, thermogenin), i.e. the one found in brown adi-
pose tissue, that ful¢ls these criteria (6). It may be noted that
UCP1 may not function by transporting protons as such; how-
ever, the net outcome of UCP1 action corresponds to a proton
transport.
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adipose tissue occurs, including a large increase in
the amount of UCP1 [5,6]. This is expected to be,
and as demonstrated below indeed is, the molecular
background for the occurrence of adaptive adrener-
gic non-shivering thermogenesis, and is based on the
well-demonstrated ability of UCP1 to allow for a
regulated re-entry of protons into the mitochondrial
matrix (or at least having this as the net e¡ect) (Fig.
1). This is also associated with a vast increase in the
metabolic response to injected norepinephrine, for
reasons that will be evident from Fig. 7. The vast
increase found in UCP1 mRNA even in moderate
cold is illustrated in Fig. 2, and may there be con-
trasted with the relatively modest or inconsistent
changes in expression of UCP2/UCP3 levels in
brown adipose tissue, muscle and other tissues dur-
ing cold acclimation.
In agreement with the data in Fig. 2, there are in
general only indications of small and probably tran-
sient increases in UCP2/UCP3 expression during
cold exposure [7^9], although it is also clear from
Fig. 2A that this conclusion is dependent on the
acclimation temperature of the ‘control’ animals.
UCP2 mRNA levels in muscle are increased only
transiently during cold exposure and only in certain
muscles [8,10^13] (Fig. 2B). Cold exposure leads to
only a transient increase in UCP3 mRNA in muscle
during the initial period of exposure [11,12]; in fully
cold-acclimated animals, the levels of UCP3 mRNA
are lower than or equal to those in warm-acclimated
animals [7,8,10,11,13]. There is thus no evidence for a
recruitment of UCP2/UCP3 in muscle in cold-accli-
mated animals, i.e. during the time when non-shiver-
ing thermogenesis is ongoing and e⁄ciency is low-
ered.
2.2. Perinatal
The perinatal state is also a state associated with
metabolic ine⁄ciency in the form of an enhanced
capacity for non-shivering thermogenesis. Despite
very variable patterns of perinatal development of
non-shivering thermogenesis, this is also well corre-
lated with UCP1 expression (as reviewed in [14]).
Thus, in the altricial (not so well-developed) young
of rats and mice etc., there is an increase in UCP1
which occurs rather slowly, within days, after birth
but which correlates well with the slowly rising abil-
ity of the animals to demonstrate non-shivering ther-
mogenesis. In contrast, the highly immature young of
golden hamsters are poikilothermic for the ¢rst 10^
12 days of life, and no UCP1 can be detected before
about postnatal day 12, at which point the animals
defend body temperature and also successively be-
Fig. 2. Only the expression of UCP1 is consistently increased in states of metabolic ine⁄ciency (here modest cold acclimation). The
¢gure compares relative e¡ects of acclimation to a cool environment of mice (from thermoneutrality at 30‡C to the relative cold of
18‡C which corresponds to a doubling of total metabolic rate in these mice) on the mRNA levels of di¡erent members of the uncou-
pling protein family. In all cases, the levels at 30‡C were set to 100, and therefore the presentation does not compare absolute levels
of mRNA. (A) UCP1, UCP2 and UCP3 mRNA levels in brown adipose tissue; note that although UCP3 mRNA levels increase be-
tween thermoneutrality and 24‡C, further cold does not lead to any further increase in levels; a continued increase is only seen for
UCP1. (B) UCP2 mRNA levels in selected tissues; no increase is seen. (C) UCP3 mRNA in muscle. Based on data in [13].
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come able to respond to a norepinephrine injection
with an increase in metabolism. Finally, in the well-
developed (precocial) young of animals such as guin-
ea pigs, UCP1 is mainly increased immediately prior
to birth. Correlated with this is the fact that these
precocial young show a good defense of body tem-
perature at birth and immediately respond to nor-
epinephrine.
UCP2/UCP3 expression in brown adipose tissue
does not follow these patterns. Thus, in mice, with
a gradually developing non-shivering thermogenesis
after birth, UCP2 is already expressed before birth,
and UCP3 is suddenly induced at birth (probably
after the ¢rst meal) and then remains high and un-
changed [9]. Similarly, in muscle, UCP3 is induced at
birth but its high expression is apparently mainly
related to the high-lipid diet of suckling and not to
thermogenesis as such [15].
2.3. Dietary overfeeding
Certain dietary regimes, especially so-called cafe-
teria diets (but also high-fat diets or high-sucrose
diets) induce an overconsumption of food and tend
to lead to mild obesity. However, these diets do not
lead to obesity to the extent which would be expected
based on the massive increase in energy which the
animals voluntarily engorge, and the diets may there-
fore be said to induce metabolic ine⁄ciency. In par-
allel, the metabolic response to norepinephrine is in-
creased. The UCP1 content in brown adipose tissue
(whether determined as mRNA level, GDP binding
or protein) is increased following these dietary chal-
lenges [16]. Thus, the increase in UCP1 correlates
again with the increase in norepinephrine response,
with decreased metabolic e⁄ciency, and with the at-
tenuation of the development of obesity.
Concerning UCP2/UCP3, these correlations do
not hold. Cafeteria diet decreases both muscle
UCP3 expression [17] and muscle UCP2 expression
[18] (but does increase UCP2 expression in brown
adipose tissue [19] which, however, also becomes
more lipid-¢lled).
A main indication for a physiological role of
UCP2 in metabolic ine⁄ciency was originally indi-
cated to be resistance against high-fat diet-induced
obesity [20]. This was based on the observation that
in white adipose tissue of the obesity-resistant A/J
mice, levels of UCP2 mRNA were higher than in
the obesity-prone (Bl/6) strain. Although this in itself
would be in accordance with an ine⁄ciency-promot-
ing role of UCP2, it has turned out that the A/J mice
also have a more recruited brown adipose tissue
(higher UCP1 expression) [21]. The resistance to
high fat diet is therefore not in itself an argument
for some energy-dissipating function of UCP2 but
may well be explained by high UCP1 levels.
For UCP2 in muscle, generally no change is re-
ported due to a high-fat diet [21^23], while increases
have been found in white adipose tissue [20,21] and
in brown adipose tissue [24,25] (or no changes
[21,23,25]). High-fat diet consistently increases
UCP3 expression in skeletal muscle [22,23,26,27],
whereas it remains unchanged [21,23] or is decreased
in brown adipose tissue [24]. Most authors conclude
that muscle UCP3 expression is regulated by the lev-
els of circulating fatty acids [15] but no other con-
sistent pattern is observable.
Thus, only changes in expression of UCP1 are
consistent with a role in regulation of metabolic e⁄-
ciency during cafeteria and high-fat feeding.
2.4. Fasting
Fasting is associated with an increased metabolic
e⁄ciency (apparently to save energy) and a decrease
in UCP1 expression and activity [28^30].
If UCP2/UCP3 are considered as uncoupling (i.e.
‘energy wasting’) proteins, the regulation of their ex-
pression during fasting must be considered paradox-
ical: fasting causes an induction of UCP3 expression
in muscles [8,31^33]. Even at thermoneutrality, under
conditions of minimal energy requirement, the levels
of UCP3 and UCP2 are increased in the muscles of
fasted rats [33], eliminating the possibility that UCP3
thermogenesis in fasting would occur in order to
meet thermoregulatory needs of the starving body.
In brown adipose tissue, the levels of UCP3
mRNA are reduced upon fasting [8,31], but expres-
sion of UCP2 mRNA is not a¡ected by fasting
[31,34] or refeeding [31].
Thus, whereas UCP1 expression is downregulated
under this condition of increased metabolic e⁄-
ciency, the behaviour of UCP2/UCP3 does not
at all ¢t with a role in determining metabolic e⁄-
ciency.
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2.5. Genetic obesity
Genetic obesity is also associated with increased
metabolic e⁄ciency. Correspondingly, genetic obesity
(ob/ob or db/db mice or fa/fa rats) is associated with
low UCP1 levels in brown adipose tissue, an inability
to tolerate cold and an increased metabolic e⁄ciency
[35^39]. When obesity is overcome, e.g. by leptin
treatment of ob/ob mice, this is associated with an
increase in UCP1 levels [40], fully in accordance
with the reoccurrence of a lower metabolic e⁄ciency.
In contrast, genetic obesity is associated with an
increase in the expression of UCP2, at least in liver
and white adipose tissue [41^44]. This again is di⁄-
cult to reconcile with a metabolic ine⁄ciency being a
consequence of UCP2 expression.
2.6. Conclusion: UCP1 but not UCP2/UCP3
expression is consistently positively associated
with metabolic ine⁄ciency
In an overall picture, it is clear that consistently,
both in cases of decreased and of increased metabolic
e⁄ciency, UCP1 expression is always positively cor-
related with metabolic ine⁄ciency. In marked con-
trast, UCP2/UCP3 expression is often positively cor-
related to metabolic ‘e⁄ciency’ states. Such ob-
servations are often referred to as ‘paradoxical’
because they would not ¢t with a thermogenic, inef-
¢ciency-promoting role for UCP2/UCP3 (but in gen-
eral may be said to ¢t with a role in lipid accumu-
lation or metabolism). Alternatively, the ‘paradoxi-
cal’ behaviour of the genes has been interpreted to
constitute a rescue function, to allow for some ther-
mogenesis even when brown-fat thermogenesis is
turned o¡, etc. A more simple explanation would
be that high UCP2/UCP3 expression does not lead
to metabolic ine⁄ciency; the function of these pro-
teins would thus not be uncoupling.
3. No adaptive non-shivering thermogenesis exists,
except that mediated by UCP1
All the above correlations between UCP1 and met-
abolic (in)e⁄ciency are exactly only this: correla-
tions. It was not until the development of UCP1-
ablated mice in the laboratory of L.P. Kozak [45]
that it became possible to unequivocally establish
the role of UCP1 as the single molecule responsible
for adaptive adrenergic non-shivering thermogenesis.
The occurrence of non-shivering thermogenesis
was described for the ¢rst time in 1954 [46]. At
that time, it was observed that although animals
that were placed in the cold initially shivered in order
to defend body temperature, with time in cold the
shivering disappeared but metabolism remained ele-
vated [47]. Thus, this elevated metabolism was
termed ‘non-shivering thermogenesis’, merely indicat-
ing that heat production was clearly occurring but in
the absence of muscular activity. It was subsequently
demonstrated that the biological agent mediating the
process was norepinephrine, released from nerve ter-
minals in the sympathetic nervous system, i.e. non-
shivering thermogenesis was adrenergically mediated
[3,48]. An injection of norepinephrine could be used
to elucidate the presence of non-shivering thermo-
genesis, and the magnitude of the response could
serve as a measure of the capacity of the animal to
perform this type of heat production [4]. As this
capacity was changeable, the process was clearly
adaptive.
As seen in Fig. 3 (left), cold acclimation of wild-
Fig. 3. Adaptive adrenergic non-shivering thermogenesis is fully
UCP1-dependent. The metabolic rate of mice was measured at
33‡C either before (3) or after norepinephrine injection (NE).
In normal mice, acclimated to a warm environment (‘warm-ac-
climated’, indicating 30‡C, i.e. thermoneutrality), norepinephrine
injection leads to a rather small increase in metabolic rate.
After the mice are acclimated to the moderate cold of 18‡C
(‘cool-acclimated’), the response is much increased. In the
UCP1-ablated mice acclimated to thermoneutrality, there is also
a response to norepinephrine injection, but the response is
smaller than in the wild-type, and is not increased by acclima-
tion to 18‡C. The di¡erence between the responses to norepi-
nephrine of similarly acclimated mice of di¡erent genotypes
may be considered to be the UCP1-dependent response; it is
clearly only this response that is increased due to cold acclima-
tion. Data from and details in [152].
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type mice leads to recruitment of adaptive adrenergic
non-shivering thermogenesis, demonstrated here as
an increased response to norepinephrine injection.
However, in the UCP1-ablated mice, although a
small response to norepinephrine occurs in the
warm-acclimated mice, no recruitment of this re-
sponse takes place (Fig. 3, right). This clearly indi-
cates that UCP1 is the only protein capable of me-
diating adaptive adrenergic non-shivering thermo-
genesis. In the absence of UCP1, animals can
respond to norepinephrine with some increase in me-
tabolism. However, this response is not recruitable,
and there is reason to doubt that it represents a
thermoregulatory thermogenesis. It is probable that
it represents the energy cost of general metabolic
reactions which are norepinephrine-stimulated and
which are also present in ectothermic animals, where
a similar norepinephrine response is observable [49^
51]. This unspeci¢c and non-thermoregulatory re-
sponse will undoubtedly dominate also in the wild-
type mice under conditions when the UCP1 level is
low (as in all animals acclimated to thermoneutrality,
not consuming a palatable diet).
The corollary to the conclusion that UCP1 is the
only protein which mediates adaptive adrenergic
non-shivering thermogenesis is, of course, that nei-
ther UCP2 nor UCP3, nor indeed any other protein,
related or not to UCP1, is able to mediate an adap-
tive adrenergic non-shivering thermogenesis. In the
UCP1-ablated animals, it would have been particu-
larly important for them to recruit alternative non-
shivering thermogenic mechanisms, if these had been
available. However, clearly no such mechanism could
be activated. This conclusion remains valid, irrespec-
tive of whether levels of expression of certain genes
in given tissues are changed or not under these cir-
cumstances, as such changes do not lead to physio-
logical responses.
It may further be understood that no other type of
metabolic event, such as substrate cycles [52] etc., is
able to respond adaptively to adrenergic stimulation
to compensate for and to provide necessary heat in
the absence of UCP1.
From the experiments above, the conclusion was
that no adaptive adrenergic non-shivering thermo-
genesis exists in the absence of UCP1. However,
the possibility may still exist that animals without
UCP1 are able to use other means, involving uncou-
pling proteins or other mechanisms, for non-shiver-
ing thermogenesis, but that the stimulatory agent for
such a process is not adrenergic. Non-adrenergic
mechanisms would escape detection when only nor-
epinephrine-induced non-shivering thermogenesis is
examined. We have therefore also examined the abil-
ity of UCP1-ablated mice to develop an alternative
means of adaptive non-shivering thermogenesis. The
UCP1-ablated mice are cold-sensitive and cannot be
transferred from normal animal house temperatures
to 4‡C, but we found, surprisingly, that preacclima-
tion of these mice to moderate cold (18‡C) allowed
them to survive full cold (4‡C), and thus, apparently,
to sustain high heat production. This heat produc-
tion may emanate from an alternative non-shivering
thermogenic process, or it may emanate from pro-
longed shivering. We therefore examined shivering
intensity in normal mice and UCP1-ablated mice
adapted to cold (4‡C). The results are summarised
in Table 1.
Wild-type mice acutely exposed to cold increase
their heat production by shivering, but with time
shivering disappears, and the high metabolic rate in
the cold is completely maintained by non-shivering
Table 1
Non-shivering thermogenesis is fully UCP1-dependent
Normal mice Mice without UCP1
in warm in acute cold in chronic cold in warm in acute cold in chronic cold
Metabolic rate low
metabolism
high metabolism same high
metabolism
low
metabolism
high metabolism same high metabolism
Shivering intensity no
shivering
high shivering no shivering no
shivering
high shivering still same high shivering
Type of
thermogenesis
basal shivering
thermogenesis
non-shivering
thermogenesis
basal shivering
thermogenesis
shivering thermogenesis
The table constitutes a summary of observations on wild-type and UCP1-ablated mice [53]. Details in [53].
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thermogenesis. However, the situation in the UCP1-
ablated mice is dramatically di¡erent: these mice also
shiver when acutely exposed to cold but they contin-
ue to do so even after prolonged exposure to cold.
Thus, the UCP1-ablated mice are unable, by any
means whatsoever, to activate a process that could
generate non-shivering thermogenesis, and they
maintain their high metabolic rate entirely through
shivering. Apparently, the ‘acclimation to cold’ in the
UCP1-ablated mice entails an increased endurance of
shivering, a muscular ‘training’ e¡ect.
This thus means that no other mechanism is
present in any organ that can take over from
UCP1 as a mediator of any form of non-shivering
thermogenesis, even after prolonged time in the cold.
UCP1 is therefore the only protein capable of medi-
ating any form of cold acclimation-recruited non-
shivering thermogenesis. No other hormone or neu-
rotransmitter that may be released by a cold stimulus
can therefore activate any such process.
The corollary concerning UCP2/UCP3 (or any
other enzyme) is, of course, that these proteins can-
not be activated to function as ‘uncoupling proteins’
even when the normal UCP1 mechanism for adaptive
non-shivering thermogenesis is ablated and the re-
quirement for heat production is therefore extreme.
Concerning the non-shivering thermogenesis and
metabolic ine⁄ciency associated with high-calorie
feeding ^ with which, as summarised above, UCP1
expression is also positively associated ^ no demon-
strations have as yet been published concerning the
essentiality of UCP1. However, under normal feed-
ing regimes (and short-time high-fat feeding), UCP1-
ablated mice living under normal animal house con-
ditions do not become obese spontaneously [45,54],
nor do UCP3-ablated mice [55,56].
4. Thermogenesis in brown-fat cells
From the responses of UCP1-ablated mice dis-
cussed above, it is clear that all adaptive adrenergic
non-shivering thermogenesis originates from the ac-
tivity of UCP1, and thus from brown adipose tissue.
The smallest unit capable of demonstrating norepi-
nephrine-induced thermogenesis is the isolated
brown adipocyte.
4.1. The UCP1 dependence of norepinephrine-induced
thermogenesis
The dramatic thermogenic (respiratory) response
of brown adipocytes to norepinephrine [57,58] is
seen in Fig. 4A. The low basal respiratory rate is
increased nearly 10-fold by the addition of norepi-
nephrine. The absolute requirement for UCP1 for
this norepinephrine-induced thermogenesis is best
witnessed in Fig. 4B: it is clear that in the absence
of UCP1, norepinephrine is unable to elicit any ther-
mogenesis. Thus, the ability of brown-fat cells to
produce heat is indeed fully dependent upon the
presence of UCP1 in these cells.
In the cells from UCP1-ablated mice, norepineph-
rine is still competent to increase cAMP levels and to
stimulate lipolysis [59]. Thus, signal transduction
pathways and substrate production are normal in
these cells. This then demonstrates that all other
mechanisms, whether mitochondrial or not, that
have earlier been suggested in brown-fat cells to be
the means of or ascribed a partial role in thermo-
genesis, are without signi¢cance in the absence of
UCP1. This includes such mechanisms as increased
plasma membrane permeability, substrate cycles, al-
tered cytoplasmic pH etc.
There are other properties which relate to UCP1
function that can be deduced from experiments of
this type.
Fig. 4. The dependence of the thermogenic response to norepi-
nephrine on UCP1. Brown-fat cells isolated from normal mice
(A) or from UCP1-ablated mice (B) were isolated and stimu-
lated with 1 WM norepinephrine (NE), and the thermogenic re-
sponse (oxygen consumption) followed. Adapted from [59].
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The basal respiratory rates of the isolated cells
from wild-type and UCP1-ablated mice are identical,
and the respiration is clearly coupled in both cell
preparations because the mitochondrial uncoupler
FCCP can increase the respiratory rate [59]. This
thus indicates that in the native state, the mitochon-
dria within the brown-fat cells are not in an innately
uncoupled state due to the presence of UCP1, but
the rate of respiration is conventionally regulated by
ADP accessibility, since substrate is evidently avail-
able. Consequently, for thermogenesis to be initiated,
UCP1 has to become activated or the transported
species has to be provided (see below).
There is a corollary to this conclusion, concerning
the function of UCP2/UCP3, since both these UCPs
are well expressed in brown adipose tissue, and since,
notably, UCP2 expression in the UCP1-ablated mice
is markedly enhanced, making brown adipose tissue
of UCP1-ablated mice probably the tissue with the
highest endogenous entopic expression of UCP2
[13,54,59]. From the studies on brown-fat cells, there
is no indication that a high expression of UCP2 (or
UCP3) in a tissue necessarily means that cells within
that tissue are in an ‘uncoupled’ state. The simple
conclusion would be that UCP2/UCP3 are not in-
nately thermogenic. This conclusion may, however,
be erroneous because it cannot presently be estab-
lished whether UCP2/UCP3 proteins are present in
the mitochondria of these cells, despite the apparent-
ly high UCP2/UCP3 mRNA levels. However, this is
not a limitation restricted to brown fat. Most studies
to date have been restricted to correlating alterations
in UCP2/UCP3 mRNA levels in any tissue with met-
abolic events and concern may therefore be felt as to
conclusions of such studies, since there is no reason
to suspect that brown adipose tissue would be the
only tissue in which UCP2/UCP3 mRNA and pro-
tein levels were not to correspond.
4.2. Fatty acid-stimulated respiration in brown-fat
cells is UCP1-dependent
Already in the ¢rst studies of norepinephrine-
stimulated respiration in isolated brown adipocytes,
it was demonstrated that addition of fatty acids
could stimulate thermogenesis in a manner apparent-
ly similar to that of norepinephrine [57,58] (Fig. 5A).
While this was interpreted as indicating a direct role
for fatty acids in initiation of the norepinephrine-
stimulated respiration, doubt has until now existed
as to the speci¢city of the response. In cells from the
UCP1-ablated mice, addition of fatty acids fails to
stimulate respiration (Fig. 5B). This demonstrates
that the fatty acid e¡ect is indeed mediated by
UCP1 and thus does mimic the physiological activa-
tion process. The magnitude of the respiratory re-
sponse can thus be taken as an indication of the
amount of available UCP1 in the individual cells
[60].
When an uncoupler is added to cells from UCP1-
ablated mice subsequent to the addition of fatty
acids, a marked stimulation of respiration is ob-
served (Fig. 5B). The cells are thus fully competent
to oxidise the added fatty acids but do not do so, as
the mitochondria are coupled. Hence, it can be con-
cluded that in UCP1-containing cells, fatty acids can
activate thermogenesis in a UCP1-dependent man-
ner, although it cannot be concluded from these
studies if their role is direct or indirect, nor if they
merely mimic the physiological activation process or
represent the true mediation pathway (see below).
As an alternative physiological activator, retinoic
acid has been recently proposed. In yeast systems
where uncoupling proteins were ectopically ex-
pressed, retinoic acid could increase proton perme-
ability [61] and this could be con¢rmed in isolated
brown adipocytes [59]. However, since the binding
a⁄nity of retinoic acid for albumin is much lower
than that of fatty acids [62,63], it is probable that
the free concentration of retinoic acid was markedly
Fig. 5. The dependence on UCP1 of the thermogenic response
of brown-fat cells to fatty acids. Brown-fat cells isolated from
normal mice (A) or from UCP1-ablated mice (B) were isolated
and stimulated with laurate (added to albumin-containing me-
dium), followed by FCCP, and the thermogenic response (oxy-
gen consumption) followed. Adapted from [59].
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higher than for the fatty acids and any physiological
role for retinoic acid is therefore as yet unclear.
However, in the absence of UCP1, retinoic acid
cannot induce a thermogenic response [59]. Thus,
the retinoic acid e¡ect is mediated by UCP1. The
corollary of these observations with respect to
UCP2/UCP3 must be that fatty acids (or retinoic
acid), at these concentrations, are unable to activate
UCP2 or UCP3 in the cell from the UCP1-ablated
mice, either because the proteins cannot be activated
by such a process or because the proteins are not
present in the cells, despite the very high mRNA
levels.
5. Thermogenesis in brown-fat mitochondria
Some of the pertinent features of the function of
UCP1 in brown-fat mitochondria can be visualised in
what may be considered a ‘classical’ mitochondrial
experiment, here compared with isolated liver mito-
chondria.
5.1. ‘Normal’ mitochondria
Liver mitochondria may be taken as an example of
‘normal’ mitochondria. The mitochondria are iso-
lated from the bulk cells of the tissue and are there-
fore practically devoid of all uncoupling proteins (in
liver, UCP2 is normally expressed only in Kup¡er
cells [64]). When isolated liver mitochondria are
added to a medium, the membrane potential is low,
but the addition of substrate leads to a rapid increase
in membrane potential, during which a transient in-
crease in respiration is observed (Fig. 6A,B). Once
high membrane potential has been generated, the
addition of GDP has no e¡ect on membrane poten-
tial (Fig. 6A), or on respiration (Fig. 6B). However,
the addition of ADP as an acceptor for oxidative
phosphorylation leads to a decrease in membrane
potential and an increase in respiration, while ADP
is being converted into ATP. Inhibition of ADP
transport into the mitochondria with atractylate in-
hibits respiration and restores membrane potential to
a high level, whereas a mitochondrial uncoupler,
FCCP, markedly stimulates respiration and dissi-
pates the membrane potential.
5.2. Normal brown-fat mitochondria
In very marked contrast, the addition of substrate
to isolated brown-fat mitochondria (Fig. 6C,D) does
not lead to mitochondrial energisation but to a very
high rate of respiration (‘thermogenesis’) (and a con-
tinued low membrane potential). It may especially be
noted that this high rate of respiration is achieved
without any addition of e.g. fatty acids, and is
equally observable even after the mitochondria
have been albumin-washed and with albumin present
in the medium. Based on studies in reconstituted
systems, it has been proposed that fatty acids are
necessary for the functioning of UCP1 [2,65^67],
and this concept has gained general acceptance. It
can, however, be clearly seen here that there would
appear to be no requirement for the addition of fatty
acids in brown-fat mitochondria in order to observe
a high level of respiration/thermogenesis.
An addition of GDP increases membrane potential
and inhibits thermogenesis. The mitochondria are
now in a coupled state. This dramatic and unique
e¡ect of GDP was ¢rst observed in 1968 [68] and
was initially interpreted as a metabolic e¡ect, depen-
dent on nucleotide uptake [69] but it was later shown
to occur on the outside of the mitochondria [70]. It
was this coupling e¡ect of GDP that led to the iden-
ti¢cation of UCP1 [71], originally as the binding pro-
tein for GDP (ADP). The conspicuous e¡ect of GDP
addition is sometimes taken to indicate that UCP1
should possess a particularly high a⁄nity for GDP;
indeed, UCP1 was often earlier referred to as the
‘GDP-binding protein’. However, numerous other
purine nucleotides (especially ATP, ADP, GTP) are
functional on the site, and the a⁄nity for GDP is not
exceptionally high [2,72]. GDP is, however, rather
uncomplicated to work with experimentally, and
for simplicity, we refer here to ‘GDP e¡ects’ but do
not by this imply a physiological role for this partic-
ular nucleotide. In all likelihood, the physiologically
active nucleotide is ATP, as it is present in the high-
est concentrations in the cytosol and can be expected
to determine also the nucleotide concentrations in
the intermembrane space to which the binding site
is exposed.
Subsequent addition of ADP to GDP-coupled
brown-fat mitochondria leads only to a marginal
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stimulation of respiration and equally marginal de-
crease in membrane potential (Fig. 6C,D). This in-
dicates that brown-fat mitochondria are only poorly
able to synthesise ATP; this is not because they are
‘uncoupled’ (have a low energisation ^ which they
clearly do not have in the presence of GDP) but
because the amount of ATP-synthase in the mito-
chondria is low, when estimated either from activity
(as illustrated here) [73,74] or from immunoblotting
[74]. Although all but one of the mRNAs coding for
the ATP synthase subunits are found at very high
levels in brown adipose tissue, expression of the F0
subunit c from its P1 gene is very limited, if not
absent, and this expression level appears to regulate
the amount of ATP synthase in brown-fat mitochon-
dria [75,76]. In consequence, the e¡ect of atractylate
inhibition of the ATP/ADP carrier is also limited,
but full uncoupling can be achieved with FCCP
(Fig. 6C,D).
5.3. Brown-fat mitochondria from UCP1-ablated mice
That UCP1 is indeed the protein enabling un-
coupled respiration in brown-fat mitochondria is evi-
dent in mitochondria isolated from animals without
UCP1 [77,78]. As seen in Fig. 6E,F, in sharp contrast
Fig. 6. Typical energisation and thermogenic responses in (A,B) liver mitochondria, (C,D) normal brown-fat mitochondria and (E,F)
brown-fat mitochondria from UCP1-ablated mice. The additions include substrate (S: succinate for liver mitochondria, glycerol 3-
phosphate for brown-fat mitochondria), 1 mM GDP, 1 mM ADP, atractylate (ATR) and FCCP. Results on membrane potential
(left) and oxygen consumption (right) are from parallel but not identical traces. The membrane potential was estimated spectroscopi-
cally by the rhodamine method; upward de£ections indicate energisations. Adapted and extended from [59,153].
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to the wild-type mitochondria, mitochondria from
the UCP1-ablated mice are fully coupled upon iso-
lation, evident both from the high membrane poten-
tial in the presence of substrate and from the low
respiratory rate. This is in accordance with expect-
ations of the role of UCP1.
However, even in the absence of UCP1, the addi-
tion of ADP does not induce a notably higher respi-
ration or decrease in membrane potential. This
means that the absence of UCP1 does not (re)intro-
duce a high level of ATP synthase [77]. Levels of
gene expression of ATP synthase subunits indicated
that although these are even higher in the brown
adipose tissue of UCP1-ablated mice, the P1 gene
of subunit c is still fully repressed [13,54]. Thus, the
absence of ATP synthase from normal brown-fat
mitochondria is not secondary to the presence of
high amounts of UCP1 in the mitochondrial inner
membrane. Finally, the large e¡ect of FCCP indi-
cated that a high respiratory capacity is maintained
even in the absence of UCP1.
The corollary concerning UCP2/UCP3 is that the
very high mRNA levels in the brown adipose tissue
of UCP1-ablated mice does not lead to any uncou-
pling in the isolated mitochondria from this tissue.
The membrane potential can be calculated to be even
slightly higher than that in liver mitochondria,
which, as emphasised above, derive from cells lack-
ing UCP2 and UCP3. There is no GDP e¡ect on
membrane potential or respiration and similarly,
there is no speci¢c GDP-binding capacity. It must,
however, again be emphasised that the presence of
the proteins in these mitochondria has not as yet
been veri¢ed.
5.4. Do UCP2/UCP3 uncouple when entopically
expressed?
In contrast to the very dramatic e¡ect of UCP1
expression on brown-fat mitochondria bioenergetics
summarised above, no consistent evidence for any
uncoupling e¡ect of UCP2/UCP3 when entopically
expressed has as yet been published. All clear evi-
dence for UCP2/UCP3 functioning as uncoupling
proteins has come from experiments where these pro-
teins have been overexpressed, ectopically or entopi-
cally. Overexpression of mitochondrial carrier pro-
teins may be associated with serious disturbances in
mitochondrial structure and function. It is notewor-
thy that even UCP1 ^ which when endogenously ex-
pressed and not acutely stimulated does not lead to
innate uncoupling (Fig. 4) ^ can do so when overex-
pressed or ectopically expressed [158]. Even when
UCP1 is entopically overexpressed (i.e. in brown adi-
pose tissue), under the aP2 promoter, this apparently
leads to such problems for the mitochondria and
cells that the cells die [79].
The reports that UCP2/UCP3 dramatically disrupt
the mitochondrial membrane potential when ex-
pressed in yeast may be indicative that the e¡ect is
rather experimental than ‘physiological’. It is espe-
cially noteworthy that UCP3 without its last trans-
membrane helix (the so-called UCP3S, only found in
humans) [80,81] and even the more mutilated mutant
with only three of the six transmembrane helices still
existing [82] are also very good ‘uncouplers’. This
may be interpreted to imply that the e¡ects observed
do not represent genuine inherent e¡ects of the func-
tional protein but rather consequences of the exper-
imental system. In this context, it may also be dis-
cussed whether the ‘uncoupling’ and ine⁄ciency-
inducing e¡ects of ectopically (over)expressed
UCP3 in the skeletal muscle of mice may ^ as also
indicated by the authors ^ rather be indicative of
mitochondrial disturbances than of innate UCP3
function [83].
Fig. 7. The accepted pathway from L-receptor stimulation to
lipolysis and fatty acid release. For evidence that this pathway
is the one that stimulates UCP1, see Table 2. The steps after
fatty acid release leading to the functional uncoupling via
UCP1 indicated here are discussed in detail in the text and in
Figs. 8^11.
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6. The question of the physiological control of UCP1
activity
6.1. The pathway from adrenoceptor activation to
fatty acid release
Although the pathway for UCP1 activation within
the brown-fat cells is still not fully clari¢ed, there is
good agreement concerning the ¢rst part of the pro-
cess. This pathway is summarised in Fig. 7 and the
evidence for it (which is actually not complete) is
summarised in Table 2. Three characteristics are
summarised in the table: whether norepinephrine ac-
tually activates the pathway step in question,
whether direct mimicking of this step also leads to
thermogenesis, and whether inhibition of this step
also inhibits thermogenesis.
6.1.1. Do alternative adrenergic pathways exist?
The presence of K1-adrenoceptors on isolated
brown adipocytes is well established [93^95] and their
coupling to Gq-linked pathways demonstrated [96^
98]. An K1-adrenergic component of norepinephrine-
stimulated respiration has been veri¢ed, although it
cannot in itself lead to signi¢cant thermogenesis.
Rather, it would seem to have a potentiating e¡ect
on L-adrenergic stimulation, leading to higher ther-
mogenesis for a given amount of cAMP through a
Ca2-dependent process [89]. It is not presently
known whether the e¡ect is on lipolysis or down-
stream from this, i.e. on UCP1 activity.
6.1.2. Do non-adrenergic pathways exist?
In certain species, a number of peptide hormones
have been shown to be able to stimulate respiration
e.g. glucagon and ACTH [99^103]. These appear to
be acting conventionally through cAMP, although
the receptor a⁄nity for these peptide hormones is
low and there is no evidence that e.g. the concentra-
tion of glucagon in the blood would ever reach the
levels necessary to stimulate thermogenesis. To our
knowledge, no cAMP-independent pathway and no
hormones not signalling through cAMP have been
shown to activate UCP1 and thermogenesis.
6.2. Fatty acid e¡ects on brown-fat mitochondria and
UCP1
It was early accepted that fatty acids liberated
from endogenous triglycerides by the lipolytic action
of norepinephrine are the substrates combusted dur-
ing UCP1-catalysed thermogenesis.
However, it is the implication from the experi-
ments indicating a direct and UCP1-dependent e¡ect
of fatty acids on brown-fat cells (Fig. 4) that fatty
acids are also intimately related to the functioning of
UCP1. At least two main roles have been discussed,
which are partly overlapping: the fatty acids may be
cofactors for UCP1 function, and/or they may, di-
rectly or indirectly, be activators of UCP1.
To review these possibilities, we ¢rst summarise
the di¡erent suggestions for the e¡ects of fatty acids
on brown-fat mitochondria.
It is generally accepted that fatty acids can uncou-
ple any kind of mitochondria [104] (although the
erroneous idea that the demonstration of fatty acid
uncoupling should in itself be indicative of the pres-
ence of uncoupling proteins is apparently becoming
Table 2
Evidence for pathway from adrenoceptor activation to thermogenesis in brown adipocytes as studied in isolated mature cells
NE activates mimicking by these agents
induces thermogenesis
inhibition of NE-induced
thermogenesis
L3-receptor L3-agonists induce [84,85] high propranolol inhibits [86]
Gs protein cholera toxin [87]
adenylyl cyclase forskolin [88,89]
cAMP cAMP levels increase [89] cAMP-analogues [87]
PKA H89 abolishes [90]
hormone-sensitive lipase is present [91]
lipolysis glycerol release [92]
fatty acids fatty acid release [92] fatty acid addition to cells
[57^59]
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rather widespread). The general interactions of fatty
acids with brown-fat mitochondria that have been
discussed include the following (Fig. 8).
(a1) At high concentrations, fatty acids may func-
tion as simple detergents, destroying the mitochon-
drial membrane [105]. This would take place in
brown-fat mitochondria as in other mitochondria
and not be UCP1-dependent, and probably not phys-
iologically relevant.
(a2) As fatty acids are ‘weak hydrophobic acids’
and thus ful¢l the criteria for functioning as classical
chemical uncouplers (such as DNP or FCCP), they
may also in brown-fat mitochondria uncouple in this
way.
(b) Certain mitochondrial carriers can mediate a
fatty acid-induced uncoupling. This was ¢rst shown
for the ATP/ADP carrier [106], and the concept has
later been broadened to other mitochondrial carriers:
the dicarboxylate [107], aspartate/glutamate [108]
and phosphate [109] carriers. The method suggested
for uncoupling in this case is rather indirect, with ^
as illustrated ^ the fatty acid entering through the
mitochondrial inner membrane in the protonated
form, in a process not catalysed by any protein,
thus again functioning as a chemical uncoupler.
The H is then released on the inside of the mem-
brane, and the carriers simply function to transport
the anionic form of the fatty acid back out of the
mitochondrion. No direct evidence has been pub-
lished as yet for this mechanism in brown-fat mito-
chondria, but it is likely that it exists.
Common for the ‘c’ alternatives below is that they
imply a speci¢c interaction of fatty acids with UCP1,
either as part of the transport process, or as a regu-
latory process.
Two of those (c1 and c2) involve the fatty acids
functioning as cofactors. Both are mainly based on
results with isolated and reconstituted UCP1. In such
preparations, there is evidence that fatty acids are
necessary for the H-conducting activity of UCP1.
However, this is not equally evident when the func-
tioning of UCP1 in its native environment is inves-
tigated. Thus, as seen in Fig. 6C,D above, isolated
brown-fat mitochondria are fully uncoupled without
the addition of fatty acids (and in the presence of
albumin as a fatty acid scavenger), and this uncou-
pling is fully UCP1-mediated, as it is inhibited by
GDP. Even high concentrations of albumin during
preparation, storage and incubation of brown-fat mi-
tochondria do not lead to a less uncoupled state.
Thus, although fatty acids are necessary in reconsti-
tuted systems, they may not be so when UCP1 is in
its native surroundings. In the reconstituted system,
other important components are perhaps missing.
However, accepting that free fatty acids are
involved, in the Skulachev/Garlid/Jezek model
sketched in c1 [65^67], UCP1 is seen as a fatty
Fig. 8. Discussed mechanisms for fatty acid e¡ects on brown-
fat mitochondria. The mechanisms include both those common
to all types of mitochondria (a,b) and those suggested to be
UCP1-dependent (c,d). It is likely that a and b will take place
also in brown-fat mitochondria, given that su⁄ciently high
amounts of fatty acids are added experimentally. Concerning
the remainder, evidence for c1 and c2 is only from reconstitu-
tion experiments, c3 lacks evidence, and c4 does not seem to ¢t
with data from brown-fat mitochondria from UCP1-ablated
mice (Fig. 10). d is a hypothetical scheme, and the identity of
the IPA, the intracellular physiological activator, is unknown.
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acid-carrying carrier, as discussed for other mito-
chondrial carriers above in b. It is clear that UCP1
can function in this way experimentally. The advan-
tage of this model is that it makes the anion-carrying
properties of UCP1 meaningful (cf. the discussion in
the legend to Fig. 9). However, it has also been
claimed that this type of function requires rather
high concentrations of fatty acids. The inability of
albumin to inhibit UCP1-mediated uncoupling is
also somewhat di⁄cult to understand in this model,
since the fatty acids should be visible from the out-
side of the mitochondria and should therefore be
captured by albumin.
In another formulation (c2), mainly promoted by
Klingenberg [2], the fatty acids have a more integral
role and function by their carboxyl groups acting as
stepping stones for the protons. The well-docu-
mented anion permeability of UCP1 is not explained
by this model.
A further issue concerning both the c1/c2 models is
that a function for the nucleotide-binding site on
UCP1 is not formulated. These models do not di-
rectly discuss the activity state of UCP1, and it is
unclear whether there is a regulatory function for
the nucleotide-binding site. Either UCP1 may be as-
sumed to be in an inherently active form, not GDP-
inhibited, but lacking fatty acids ^ and it can then be
understood why fatty acid addition to cells is su⁄-
cient to cause uncoupling, as they provide the shuttle
for the protons. Alternatively, UCP1 may be consid-
ered to be in the inactive, GDP-inhibited form, even
when fatty acids are supplied, but then another
mechanism for UCP1 activation has to be suggested
(which should also be fatty acid dependent, based on
the cell experiments in Fig. 4).
Common for the models c3 and c4 below is that
they imply a regulatory role of fatty acids.
(c3) It appears not to be uncommon to visualise
that fatty acids overcome the nucleotide inhibition by
a direct competitive mechanism. However, no com-
petitivity has been shown between fatty acids and
GDP binding in isolated mitochondria [110], and
this model seems presently excluded.
(c4) In this formulation, the fatty acids interact
instead with a site other than the GDP-binding site
and in this way activate UCP1. In this model, mainly
promoted by Nicholls/Rial [111^113], the nucleotide-
binding site is again without apparent regulatory
function, which from a teleological point of view
feels less satisfying. It has been discussed that the
nucleotide-binding site could in some way a¡ect the
sensitivity to fatty acids. However, in a series of ex-
periments, investigating the in£uence of membrane
potential on the uncoupling ability of fatty acids,
we observed that the ability of fatty acids to uncou-
Fig. 9. The question of the transported species. In this sketch,
di¡erent models for the function of UCP1 are discussed. The
models either consider UCP1 to be a bona ¢de proton conduc-
tor (left models) or an anion carrier (right models), and they
imply that UCP1 can function in itself (top models) or needs
fatty acids for function (bottom models). Whereas the simplest
model is A, which cannot be refuted based on mitochondrial
studies alone, this mechanism ignores the remarkable Cl3 (and
many other anions)-carrying ability of UCP1 [159,160]. In a re-
formulation of this model by Nicholls [154] (B) it was suggested
that uncoupling was instead due to an e¥ux of OH3 that
would neutralise the H pumped out of the mitochondrion,
and thus in reality annihilation of the proton gradient and thus
uncoupling would be achieved. If a need for fatty acids for
UCP1 function is accepted, the models become reformulated to
include a fatty acid as a stepping stone for the H (C), as for-
mulated by Klingenberg [2]. In parallel, the anion-carrying
property may be reformulated to imply that UCP1 carries fatty
acid anions out of the mitochondria after they have passively
transported protons in through the mitochondrial membrane
[66] (D). No fully convincing evidence has been presented for
any of these four models in an intact system. We would tend
to consider B the one that is simplest in summarising known
properties of UCP1 in situ. Scheme adapted from [54].
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ple was membrane potential-dependent, but this de-
pendence was the same whether the membrane po-
tential was altered in a UCP1-dependent manner
(with GDP) or a UCP1-independent manner (with
FCCP) (Matthias et al., unpubl. obs.).
However, more importantly, experiments with iso-
lated mitochondria do not substantiate a direct inter-
action of fatty acids with UCP1. Experiments of this
type are summarised in Fig. 10. In these experiments,
the ability of fatty acids to uncouple (de-energise)
mitochondria was investigated. Wild-type, UCP1-
containing brown-fat mitochondria were ¢rst ener-
gised with GDP (as in Fig. 6C) and then the ability
of fatty acids to de-energise the mitochondria was
studied (¢lled points). (It will be understood that it
is not possible to study the e¡ect of fatty acids as
uncouplers of brown-fat mitochondria in the absence
of GDP, because the isolated mitochondria are al-
ready fully uncoupled (Fig. 6B,C) and no further
e¡ects of fatty acids can be obtained.) Already at
very low free concentrations of fatty acids, a substan-
tial decrease in membrane potential was observed.
However, when the same experiment was performed
with brown-fat mitochondria from UCP1-ablated
mice, approximately the same de-energisation was
observed. Thus, this uncoupling (de-energising) e¡ect
of fatty acids on isolated brown-fat mitochondria
was not UCP1-dependent.
Isolated liver mitochondria from the same animals
were much less sensitive to the de-energising e¡ect of
fatty acids (Fig. 10). Thus, although the type of mi-
tochondria studied can in£uence the results obtained,
probably dependent upon di¡erent membrane com-
positions, the di¡erence in sensitivity is clearly not
due to the presence of UCP1. Thus, we see no indi-
cation that the presence of UCP1 conveys a high
fatty acid sensitivity to mitochondria. Rather, the
fatty acid-induced uncoupling observed in isolated
mitochondria is probably due to mechanisms a and
b in Fig. 8, and there are di¡erences between liver
and brown-fat mitochondria which are not second-
ary to the presence or absence of UCP1.
(d) Bearing in mind the ability of added fatty acids
to activate brown-fat cells in a UCP1-dependent way
(Fig. 5), we suggest rather that it is not the fatty
acids themselves but some kind of metabolite (the
‘intracellular physiological activator’) that activates
UCP1 (model d in Fig. 8). We suggest that this is
by competition with nucleotides bound to the nucle-
otide-binding site on UCP1, but we have no evidence
for this.
The intracellular physiological activator has earlier
been suggested to be the ‘activated’ form of fatty
acids, the acyl-CoA esters. A series of observations
have earlier been made in support of this
[110,114,115]. Palmitoyl-CoA has been shown to
bind competitively and reversibly to the same site
as the nucleotides (perhaps not surprisingly, since
an ADP moiety is an integral part of CoA). There
Fig. 10. The high sensitivity of brown-fat mitochondria to free
fatty acids is not due to UCP1. As compared to liver (F),
brown-fat mitochondria (b) demonstrate a high sensitivity to
the uncoupling (here de-energising) e¡ect of fatty acids. This
high sensitivity has generally been assumed to be due to the
presence of UCP1 in the brown-fat mitochondria, especially as
the sensitivity to fatty acids seems to correlate with the amount
of UCP1 during di¡erent degrees of recruitment [122]. How-
ever, unexpectedly, the high sensitivity to fatty acids is also ob-
served in brown-fat mitochondria from UCP1-ablated mice (a),
still as compared to liver mitochondria from these mice (E)
(data from [54,77,155]). The apparent correlation between
UCP1 amount and fatty acid sensitivity observed is one of the
major arguments for a regulatory role of fatty acids on UCP1
activity [122]. As the high sensitivity of brown-fat mitochondria
is not caused by UCP1, the molecular background for this sen-
sitivity is now unknown. An unexplored question is also as to
whether recruitment alters fatty acid sensitivity even in the ab-
sence of UCP1. The high sensitivity to fatty acids is not equally
evident if actual thermogenesis rather than mitochondrial de-en-
ergisation is followed: due to di¡erent vO2/vmembrane poten-
tial relationships in liver and brown-fat mitochondria, there is
only a marginal thermogenic hypersensitivity to fatty acids in
brown-fat mitochondria as compared to liver mitochondria
[155].
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is also some evidence that acyl-CoA can re-activate
GDP-inhibited UCP1 [110,116]. However, no direct
evidence has as yet been presented that the acyl-CoA
is the intracellular physiological activator of UCP1.
6.3. Summary: the four discussed pathways
Four suggestions presently discussed for the path-
way leading from activation of brown-fat cells by
norepinephrine to thermogenesis are summarised in
Fig. 11.
In the pathway summarised in Fig. 11A (‘non-in-
hibited UCP1’), the implicit starting point is that
within the cells UCP1 is never in an inhibited state,
because the intracellular nucleotides (ATP in partic-
ular) (that so clearly inhibit brown-fat mitochondria
in the isolated state (Fig. 6B,C)) do not in£uence
UCP1 in vivo. An argument for this is that it is
the uncomplexed form of nucleotide that binds and
inhibits UCP1 [117], and the level of this uncom-
plexed form may be suggested to be low in the cyto-
sol. However, in isolated mitochondria, GDP inhibits
with an EC50 of only 30 WM even in the presence of
1 mM free Mg2 [77]; with cytosolic nucleotide con-
centrations in the millimolar range, apparently su⁄-
cient free nucleotide would remain to be able to in-
hibit. It may also be proposed that there may be
problems for cytosolic nucleotides to equilibrate
with the intermembrane space, to which the nucleo-
tide-binding site of UCP1 is apparently facing. While
this cannot be excluded, it is perhaps surprising that
there is apparently no problem in connection with
ATP synthesis when ADP has to gain access to a
similar carrier in the intermembrane space. In this
formulation, there is also the problem, albeit teleo-
logical, that the nucleotide-binding site does not have
a function. However, the point would be here that
UCP1 is ‘waiting’ for released fatty acids to function
as a cofactor, and in this way regulation is uncom-
plicated.
In the formulation in Fig. 11B, it is suggested that
a signal other than the fatty acids themselves can
activate UCP1. In one version, this signal has been
suggested to be an intracellular alkalinisation. An
e¡ect of (extracellular) alkanisation on thermogenesis
was an early observation [118], and it may be com-
bined with the fact that nucleotide binding to UCP1
is markedly pH-dependent [72,119]. It could there-
fore be hypothesised that an increased pH would
dramatically decrease nucleotide a⁄nity for UCP1,
provided that the nucleotide concentration is close
to the Kd. There are, however, several problems
with this proposal. The reported intracellular pH
changes are very low, only 0.2 pH unit or less
[120,121]. However, most clearly, the observation in
Fig. 5 that addition of fatty acids to cells is su⁄cient
to activate thermogenesis in a UCP1-dependent man-
ner indicates that all proposals that include adrener-
gically induced events, di¡erent from stimulation of
lipolysis, can apparently be excluded.
The formulation in Fig. 11C is probably the one
that is most generally accepted currently. It states
that the fatty acids released from the triglycerides
directly activate UCP1. Support for this model
comes from the observations that fatty acid addition
to brown adipocytes stimulates respiration and that
this e¡ect of fatty acids is UCP1-dependent (Fig. 4).
Fig. 11. Pathways for activation of UCP1 presently discussed.
As discussed in the text, available evidence may tend to indicate
D as the simplest model presently. Modi¢ed from [59].
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Thus, no cellular experiments contradict this hypoth-
esis. However, although there appears to be a good
correlation between the sensitivity of brown-fat mi-
tochondria to fatty acids and the presence of UCP1
[122] and it therefore has been generally accepted
that the fatty acid e¡ects in isolated mitochondria
are UCP1-dependent, direct examination of this in-
dicates that the high fatty acid sensitivity is an inde-
pendent property of brown-fat mitochondria (Fig.
10). This property may still be related to mitochon-
drial recruitment but its UCP1 independence makes
it unlikely that the e¡ect of fatty acid addition to
cells should be understood as a direct activation of
UCP1 within the cell.
The formulation in Fig. 11D is the one that we
have been forced to forward, based on our combined
cellular and mitochondrial experiments, that the in-
tracellular physiological UCP1 activator is some type
of metabolite of fatty acids. A major problem with
this hypothesis is the lack of identi¢cation of this
intracellular physiological activator.
7. Unique structural features of UCP1 versus common
structural features of UCP1/UCP2/UCP3
The apparent inability of UCP2/UCP3 to be able
to substitute for UCP1 in any physiological context
studied to date, and the apparent inability of UCP2/
UCP3 to uncouple when endogenously expressed,
emphasise the importance of examining which struc-
tural features in the UCP1 molecule convey the
unique thermogenic function to UCP1.
We have therefore examined all published UCP1,
UCP2 and UCP3 sequences from di¡erent species.
The three UCPs, just as all other mitochondrial car-
riers, are tripartite structures, principally consisting
of 3 semi-conserved repeats of about 100 amino acid
residues each. First we established for each uncou-
pling protein the 100% conserved residues among
di¡erent species. These residues necessarily include
all residues that are essential for function. From
this compilation we have deduced three groups of
interesting residues (Fig. 12).
One group consists of the hyperconserved residues,
i.e. residues fully conserved three times in each pro-
tein and in all three UCPs. This includes the proline
at about 32/132/231, fully conserved on all three oc-
casions in all three UCPs: Px(D/E)xxxxR; this se-
quence corresponds to the general mitochondrial
carrier motif [123]. The hyperconserved residues
also include the glutamate at about 68/167/261,
followed fully conserved by the sequence:
EGxxxxxxGxxxxxxR (with the exception that
UCP1s sometimes have an S after the E in the mid-
dle loop). Although these residues are without doubt
essential for the UCP1/UCP2/UCP3 structure (and
are more or less general for all mitochondrial car-
riers), they can hardly be considered to be of unique
interest for UCP1. Mutations and deletions of some
of these residues in UCP1 have been examined, but
as such alterations probably destroy the basic struc-
ture for any carrier protein, they are probably not
indicative of speci¢c UCP1 functions.
The second group concerns the nucleotide-binding
site. These residues are fully conserved between
UCP1/UCP2/UCP3, even though nucleotide binding
has only been unequivocally demonstrated for
UCP1. Three series may be discussed. One is
the ‘Klingenberg series’, consisting of E190, (sug-
gested) D209 and H214 [2]. The second is the ‘Bouil-
laud series’, identi¢ed by being similar to DNA-bind-
ing domains of transcription factors, especially
268KGF [124]; these two series are quite distant in
the sequence but may be close spatially. To these we
would, without experimental evidence, add a partic-
ular sequence 273SFLR which may be closely located
to the nucleotide-binding site and is also fully con-
served among all the UCPs.
However, in addition to some individual amino
acids, two very speci¢c sequences (motifs) are fully
conserved in UCP1 and not found at all in UCP2/
UCP3. One is the sequence 144SHLHGIKP which is
probably located on the matrix side of the mem-
brane. Remarkably, this sequence includes the histi-
dines found in mutation experiments to be necessary
for UCP1 proton transport [125] but which are not
conserved in UCP2/UCP3. Thus, the absence of this
motif in UCP2/UCP3 is spectacular. This motif is
not presently reported in any protein in the data-
bases other than the UCP1s.
The other motif is the C-terminal sequence
RQTXDC(T/A)T which is localised on the cytosolic
side of the membrane [126] and is antigenic [127].
Also this motif is absent in any protein in the data-
bases except for the UCP1s.
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8. Control of UCP1 amount
The tenet earlier formulated [128] and now con-
¢rmed [53] ^ that it is the total amount of UCP1
in an animal that determines its capacity for non-
shivering thermogenesis, and in this way its metabol-
ic e⁄ciency ^ accentuates the interest in the control
of the actual amount of UCP1 in a mammal. The
¢nal amount of UCP1 is the outcome of a series of
controlled processes. It may be controlled at the level
of gene expression and through mRNA stability.
There are also translational aspects, and UCP1 pro-
tein stability and turnover may be altered, all factors
which combine to determine the ¢nal level of UCP1.
8.1. At the species level
The ¢rst requirement for having UCP1 in any mi-
tochondria is that its gene is found in the genome.
UCP1 is only found in mammals. Indeed, it may
be speculated as to whether the physiological evolu-
tion of UCP1 and brown adipose tissue were not
more important features contributing to the success
of mammals than the ability to feed our young
Fig. 12. Structural aspects of UCP1 versus other UCPs: unique and common features. On a principal tripartite transmembrane struc-
ture, the amino acid residues which are fully conserved in all species in all three 100-residue repeats of UCP1, UCP2 and UCP3 are in-
dicated with normal capital letters (numbering refers to hamster UCP1, with the N-terminal methionine (which is not in the ¢nal pro-
tein) having number 0); all UCP1s have E134 and UCP2/UCP3s have D134; all UCP2/UCP3s have G168 but for UCP1 half the
species have S168. The residues that are fully conserved in all three and constitute the nucleotide-binding site are indicated with italic
letters. However, most interest should be given to the two UCP1-speci¢c sequences that are fully conserved among all UCP1 sequences
published but are not at all conserved in UCP2 and UCP3; these are indicated with large bold letters. It is very likely that these two
sequences are intimately associated with UCP1 functioning. Non-capitalised letters indicate that one published sequence does not have
the indicated residue; sequencing errors cannot fully be excluded. Published sequences from the Swiss Protein data base were analysed.
UCP1 sequences included in the analysis were cow, Djungarian hamster, man, mouse, pig (partial), Syrian hamster, rabbit and rat; a
partial and uncon¢rmed sequence from shrew [156] deviates slightly from the general picture and has not been included. For UCP2,
the sequences were from carp, Djungarian hamster, dog, man, mouse, pig and zebra ¢sh, and for UCP3 cow, dog, man, Djungarian
hamster, mouse, pig and rat. The authors would like to thank Martin Klingenspor for access to the Djungarian hamster sequences be-
fore release. See also [157] for another type of analysis.
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(which has its parallels even in non-mammalian spe-
cies).
In contrast, the species distribution of UCP2 is
clearly much broader. Especially the presence of
UCP2 in ¢sh [129] (notably similar to mammalian
UCP2, making the identi¢cation unquestionable) is
remarkable in thermogenic contexts. Its presence in a
poikilothermic organism makes a thermogenic func-
tion unlikely and indicates a more ancient evolution
of this protein than of UCP1. UCP3 has not as yet
been identi¢ed in other chordate groups than mam-
mals.
8.2. Tissue-speci¢c expression
To say that UCP1 is only expressed in brown-fat
cells is tautological, because it has become a func-
tional de¢nition of brown adipose tissue that it is a
tissue in which UCP1 may be expressed. Similarly, a
functional de¢nition of brown-fat cells is cells that
have the potential to express UCP1 (although they
may not acutely do so). A few reports concerning
UCP1 expression in e.g. muscle under special phar-
macological conditions have not as yet been cor-
roborated.
In contrast, UCP2 has a very diverse expression
pattern, which does not in itself allow any simple
association with function, given our present metabol-
ic understanding. For UCP3, the distribution would
seem to be associated with a role in lipid catabolism
(in heart, brown adipose tissue and certain muscle
¢bres).
However, it should be pointed out that
UCP2+UCP3 are in no way ubiquitously expressed
in the mitochondria of the mammalian organism.
This is an important theoretical limitation consider-
ing three of the advocated ideas concerning the phys-
iological function of these proteins: basal metabo-
lism, thyroid hormone-stimulated metabolism and
protection against reactive oxygen species.
They have been proposed as being important fac-
tors in ‘basal metabolism’, in the sense that they
could generate the mitochondrial leak that is observ-
able in isolated mitochondria from any tissue and
which has been suggested to be the determinant for
basal metabolism [130].
Mediation of the e¡ect of thyroid hormone on me-
tabolism has also been suggested to be through these
proteins [31]; indeed, the level of UCP3 mRNA in
muscle is increased due to T3 treatment [31]. How-
ever, the thermogenic response to thyroid hormone
(T3) turns out to be equally high in mice devoid of
UCP3 as in wild-type mice [55] and simply for this
reason, it is unlikely that T3 mediates thyroid e¡ects.
It has also been suggested that protection against
free oxygen radical formation could be brought about
by these proteins [131]. An analysis of the physiolog-
ical relevance of UCP2/UCP3 in these contexts is
complicated by the assays presently used for inves-
tigation of the formation of reactive oxygen species.
Counter-intuitively (based on the general assumption
that reactive oxygen species (ROS) are produced
under conditions of high metabolism (high oxygen
consumption)), ROS formation is experimentally de-
termined under conditions of low oxygen utilisation
and high mitochondrial membrane potential. Thus,
any agent which lowers mitochondrial membrane po-
tential would lead to a decrease in ROS formation.
However, concerning all three proposals, they all
imply that UCP2/UCP3 are indeed functional uncou-
pling proteins, and the evidence for this ^ when they
are endogenously expressed ^ is weak. As the re-
ported e¡ects of ablation of UCP3 are inconsistent,
with some [56] or no e¡ect [55] on isolated muscle
mitochondrial basal (‘state 4’) respiration being re-
ported, the elucidation of this point is di⁄cult. More
importantly, each of these three suggested functions
needs to be ubiquitous in the mammalian organism.
Considering the fact that thyroid-induced metabo-
lism and a signi¢cant component of basal metabo-
lism are believed to occur especially in liver mito-
chondria, it is particularly noteworthy that liver
mitochondria are normally devoid of UCP2/UCP3.
It would seem inconsistent to propose that these
functions are mediated by UCP2/UCP3 in some tis-
sues but by something else in liver. There is, of
course, a possibility that further ‘uncoupling pro-
teins’ may exist and be functional in tissues devoid
of UCP2, but this possibility is becoming less likely
as gene sequence information becomes more and
more extensive. Even those sequences most recently
identi¢ed and now referred to as UCP4/UCP5/
BMCP1 etc. are not more closely related to UCP1
than they are to the oxoglutarate carrier [161], and
the implication that they should also have ‘uncou-
pling’ as their function is therefore strained. The
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same may be said about the closest plant homologue,
PUMP [161].
8.3. At the gene expression level
The expression of UCP1 is positively correlated
with metabolic ine⁄ciency and is physiologically in-
creased under conditions of decreased metabolic e⁄-
ciency. That the same agent, norepinephrine, released
from sympathetic nerves, is responsible both for reg-
ulation of gene expression and for activation of ther-
mogenesis seems therefore physiologically logical,
although it is not immediately evident how this is
achieved.
The main pathway from the L3-adrenoceptor to
gene expression is summarised in Fig. 13 and the
evidence is presented in Table 3.
In this table, the involvement of each step is exam-
ined for three criteria: the mediatory step must be
activated by norepinephrine, activation of this step
must in itself be able to mimic the e¡ect of norepi-
nephrine, and inhibition of this step must inhibit the
e¡ect of norepinephrine.
8.3.1. Non-adrenergic pathways
Although we consider it likely that it is the nor-
epinephrine-induced pathway for UCP1 control that
is the physiologically most signi¢cant, a series of
other factors may in£uence UCP1 gene expression.
It has been suggested that thyroid hormone is essen-
tial for regulated UCP1 expression [136]. However, it
is still unclear as to whether this is a direct e¡ect on
regulatory elements in the UCP1 gene itself, or
whether thyroid hormone is essential for processes
in the adrenergic intracellular cascade. Also activa-
tors of PPARQ such as pioglitazone [137] and prob-
ably essential fatty acids [138] activate UCP1 gene
expression, as do retinoids probably through both
the RXR and RAR receptors [139,140]. UCP1 gene
expression cannot be induced by norepinephrine in
immature brown adipocytes [132]. This is probably
due to an inhibitory e¡ect of c-Jun [134].
8.4. Stability of UCP1 mRNA
The level of UCP1 mRNA ^ which appears to
directly determine the rate of synthesis of the protein
^ is not only determined by the rate of transcription
but also by the rate of degradation (Fig. 13). In
brown adipocytes in culture, norepinephrine has a
stabilising e¡ect on UCP1 mRNA, increasing the
half-life from about 3 h to at least 20 h, i.e. an e¡ect
enhancing the increase in mRNA levels resulting
from an increased rate of transcription [141]. In con-
trast, in intact animals, a paradoxical shortening of
Table 3
Evidence for the pathway leading from adrenoceptor stimulation to UCP expression as studied in cultured brown adipocytes
NE activates mimicking by these agents
induces ucp1 expression
inhibition of NE-induced
ucp1 expression
L3-receptor L3-agonists induce [132] propranolol inhibits [132]
Gs protein cholera toxin [133]a
adenylyl cyclase forskolin [132]
cAMP cAMP levels increase cAMP-analogues [132]
PKA PKA is activated [90] PKA catalytic subunit [134] H89 abolishes [90]
CREB CREB is phosphorylated [90]
CRE CRE sites exist [135]
aStudied in intact animals.
Fig. 13. The pathway from L3-receptor stimulation to UCP1 in-
corporation in the mitochondrial membrane. The experimental
evidence for the indicated pathway is summarised in Table 3.
The degradative pathways are indicated with broken arrows.
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half-life occurs in the cold, from about 18 h to about
3 h [142^144]. The cause and e¡ect of this are not
known.
8.5. At the protein level
A good correlation is found between steady state
UCP1 mRNA levels and UCP1 protein levels [145],
and no regulatory elements for translational control
have as yet been identi¢ed in UCP1 mRNA.
In contrast, in the 5P-untranslated region of the
mRNA of the UCP2 gene, an open reading frame
for a putative peptide of 36 residues has been iden-
ti¢ed [146]. Although the authors did not ¢nd any
negative (or positive) in£uence of the presence of this
open reading frame on translation in vitro, such
open reading frames have been demonstrated for
other proteins to be able to regulate translation e⁄-
ciency [147]. Thus, there may be reason to consider
at least for this protein whether mRNA levels and
protein levels correspond. This issue cannot presently
be resolved, due to the lack of reliable UCP2 anti-
bodies.
8.5.1. An obligatory time delay
Although there is good correspondence between
steady-state UCP1 mRNA and protein levels [145],
this is not the case during transition phases. While
rapid changes in UCP1 mRNA have been observed,
at least in mice and rats, the necessary time delay
between changes in UCP1 mRNA and UCP1 protein
that is inherent in such a system, in the absence of
alterations in translation e⁄ciency, is not generally
recognised. Thus, with a half-life of UCP1 of about 5
days, it takes about 10 days for an alteration in
UCP1 mRNA levels to become evident as equivalent
changes in protein (Fig. 14). Thus, the observation
that e.g. starvation leads to an acute decrease in
UCP1 mRNA levels that is not accompanied by sim-
ilar changes in protein [148] is fully compatible with
the mRNA levels regulating the protein levels.
Although nothing is presently known about the
half-life of UCP2 and UCP3, it would be anticipated
that, being mitochondrial membrane proteins, they
should have a half-life of the same order of magni-
tude as that of UCP1. It is therefore unlikely that
transient alterations in UCP2/UCP3 mRNA levels ^
which have been amply reported ^ are indicative of
similar alterations in the amount of UCP2/UCP3 at
the protein level and therefore in UCP2/UCP3 func-
tion. However, changes in translational e⁄ciency
cannot be excluded for these proteins.
A pool of newly synthesised UCP1 exists, with a
half-life of only some hours [149]. This probably
represents protein not yet incorporated into the mi-
Fig. 14. The delay between increase in UCP1 mRNA amount
and UCP1 protein amount. (A) Summary of a simple model
describing the control of the level of UCP1. The model assumes
that the rate of synthesis of UCP1 protein is always directly
proportional to the amount of UCP1 mRNA (Rt) (i.e. that no
translational control occurs) and that the rate of degradation of
UCP1 protein is directly proportional to the amount of UCP1
(Pt) (¢rst order kinetics). (B) Calculated outcome of the model
in A, based on a rapid (approx. 4 h) but persistent 5-fold in-
crease in UCP1 mRNA levels (left) and on three di¡erent rates
of UCP1 turnover: half-times of 2, 5 and 20 days, as indicated.
Included are also experimental points from an actual experi-
ment, investigating UCP1 protein amounts (and mRNA levels)
during the control-to-cold transition in mice (from [145]) ; these
points fall close to the mathematical prediction for a 5 day
half-life for UCP1 (which is also the outcome of independent
experiments concerning UCP1 half-life in situ [149]). It may be
realised from these kinetics that more transient changes in
UCP1 mRNA levels would lead to much more blunted and de-
layed e¡ects on UCP1 protein levels. Evidently, the same
blunted and delayed e¡ects would be predicted from this model
for any other (mitochondrial membrane) proteins with a slow
turnover, such as UCP2 and UCP3 would probably have.
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tochondria. The UCP1 is then incorporated into the
mitochondria. Mitochondrial import and incorpora-
tion apparently depend on sequences in the ¢rst [150]
or central [151] matrix loop. When within the mito-
chondria, the half-life of UCP1 is much longer,
about 5 days [149].
9. Conclusions
Apparently close precursors to an uncoupling pro-
tein have been in the genome for a long time: at least
UCP2 would seem to have been in function much
before the ¢rst tetrapods occurred. However, to be
similar in structure is not the same as to be identical
in function, and the indications that the precursors
of UCP1 (i.e. UCP2 or UCP3) have uncoupling and
a decrease in metabolic e⁄ciency as their function
are, in our opinion, weak. However, subtle alter-
ations in the structure of these precursors were su⁄-
cient to endow the resulting protein (UCP1) with a
fully new function: that of a regulated high proton
permeability over the mitochondrial membrane, lead-
ing to a decrease in metabolic e⁄ciency. The present
success of mammals indicates that such an apparent-
ly negative property as metabolic ine⁄ciency may
lead to unexpected advantages.
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